Moderate riskFDA DrugClass II

New Life Pharma Nomida semaglutide injection recalled for sterility concerns

New Life Pharma is recalling Nomida semaglutide 2 mg injection vials because the sterility of the product cannot be assured. The affected vials may not be safe to use. This recall affects a limited quantity distributed in Ohio.

From the FDA notice · Read the official notice ↗

What to do

  1. Stop using the recalled semaglutide vials immediately
  2. Check if you have lot 240903 (expiration 9/30/2026)
  3. Contact your pharmacy or doctor for a replacement or alternative medication
  4. Do not inject any doses from affected vials

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Sold in
OH
Made for
Adults (0 months and older)

This recall covers 4 products — see all of them.

Details

Units affected
2 vials
Illnesses reported
None reported
Manufactured in
265 Livingston St, N/A, Northvale, NJ, United States
Classification
Class II
Recall number
D-0393-2026

In the FDA's words

Description
Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06 Lack of Assurance of Sterility Lot 240903, exp 9/30/2026 Distribution: OH Affected quantity: 2 vials
Hazard
Lack of Assurance of Sterility

4 products in this recall

Nomida semaglutide and tirzepatide vials recalled for sterility concerns

New Life Pharma is recalling four sterile multi-dose vials of semaglutide and tirzepatide injection, all sold under the Nomida name, because the company cannot assure they are sterile. The recall covers 2 mg and 10 mg semaglutide vials and 10 mg and 15 mg tirzepatide vials, and the products were distributed in Ohio. No injuries have been reported.

The agency lists each product separately. Check every one you might have.

Related topics